# Barley Leaves Improves Loperamide-Induced Constipation via Gut Barrier and Microbiota Modulation in Mice

**Authors:** Yuting Xu, Zhiqian Wu, Matthew Lee Cohoon, Mengting Ma, Zhongquan Sui, Harold Corke

PMC · DOI: 10.3390/foods15010095 · Foods · 2025-12-29

## TL;DR

Barley leaves may help prevent constipation in mice by improving gut function and microbiota balance.

## Contribution

This study reveals that barley leaves modulate gut barrier and microbiota to alleviate constipation in a mouse model.

## Key findings

- High-dose hulless barley leaves significantly increased stool weight and amount in constipated mice.
- Barley leaves modulated gut hormones and normalized expression of colonic AQPs and 5-HT4R.
- Barley leaves altered gut microbiota by increasing Bacteroides and decreasing Akkermansia.

## Abstract

Constipation is a common gastrointestinal disorder that seriously affects quality of life and is associated with multiple secondary complications. Barley leaves (BLs) have been suggested as potential functional foods for constipation prevention. Here, we investigated the preventive effects of common barley leaves (CBLs) and hulless barley leaves (HBLs) in a loperamide-induced constipation model in C57BL/6 mice. Both BLs improved stool parameters and gastrointestinal transit. Notably, high-dose HBLs increased stool weight to 263.84 ± 66.70 mg and stool amount to 250.20 ± 66.88 pellets, which were 12.7 and 11.1 times higher than those in the model group, respectively. BLs also modulated gut motility-related hormones (MTL, SP, Gas, SS, and VIP) and normalized colonic AQP3, AQP4, and 5-HT4R expression levels. Furthermore, BLs enhanced SCFAs production and modulated gut microbiota by increasing Bacteroides abundance and decreasing Akkermansia abundance. CBLs and HBLs also exhibited distinct mechanisms. High-dose CBLs affected SERT expression, whereas HBLs uniquely decreased Alistipes abundance and increased SCFA production. These findings suggest that BLs may help prevent loperamide-induced constipation in mice by modulating the gut barrier and microbiota. Future studies should identify key active components and validate efficacy in longer-term and clinical studies.

## Linked entities

- **Genes:** Mtl (Mig-2-like) [NCBI Gene 43319], TFF2 (trefoil factor 2) [NCBI Gene 7032], GAST (gastrin) [NCBI Gene 2520], FDFT1 (farnesyl-diphosphate farnesyltransferase 1) [NCBI Gene 2222], VIP (vasoactive intestinal peptide) [NCBI Gene 7432], AQP3 (aquaporin 3 (Gill blood group)) [NCBI Gene 360], AQP4 (aquaporin 4) [NCBI Gene 361], HTR4 (5-hydroxytryptamine receptor 4) [NCBI Gene 3360], SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532]
- **Chemicals:** loperamide (PubChem CID 3955)
- **Diseases:** constipation (MONDO:0002203)

## Full-text entities

- **Diseases:** Constipation (MESH:D003248), gastrointestinal disorder (MESH:D005767)
- **Chemicals:** MTL (-), SP (MESH:C000604007), SCFA (MESH:D005232), Gas (MESH:D005708), Loperamide (MESH:D008139)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Alistipes (genus) [taxon 239759], Bacteroides (genus) [taxon 816]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12785950/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12785950/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC12785950/full.md

---
Source: https://tomesphere.com/paper/PMC12785950